The abstract is read at the publisher; the summary is JClub's.
CD45RA-depleted T-cell therapy achieved an 88.24% overall response in 17 pediatric and adult allo-HCT recipients with refractory EBV infection, with 1-year overall survival of 76.47%.
- Why it matters: Outcomes after allo-HCT are poor for EBV infection that is refractory to rituximab, with or without chemotherapy, leaving a need for alternative adoptive cellular strategies.
- What they did: In a multicenter retrospective cohort, patients received CD45RA-depleted ACT after ≥1 line of anti-EBV therapy failure; the first infusion occurred at a median 117 days post-transplant with a cumulative 20×10^6 cells/kg.
- The result: EBV DNA clearance at 90 days was 82.35% (95% CI 48.18%–94.97%), and emergent adverse events included acute GvHD in 2 patients (11.76%) and chronic GvHD in 7 (41.18%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.